NeoClone
Through a lot of hard work, a license from the Wisconsin Alumni Research Foundation (WARF) and a desire to have an impact on human health, NeoClone was founded in 1999 by three University of Wisconsin scientists who recognized the need for better ways to discover and develop antibodies. As they refined the process to make better antibodies (what is now the NeoAb process), they established a service business to make high-quality antibodies for others. By 2002 the founders realized a need to bring in business expertise to help grow the company by leveraging its ability to make excellent antibodies. This change in direction is the foundation of what NeoClone is today - a company focused on developing high quality antibodies for sale as reagents and establishing partnerships and collaborations to develop diagnostics. As a result of these efforts, we now have over 1000 customers in 30+ countries.
Company details
Find locations served, office locations
- Business Type:
- Manufacturer
- Industry Type:
- Pharmaceuticals
- Market Focus:
- Globally (various continents)
- Year Founded:
- 1999
About Us
To poise ourselves for future success, we've continued to refine our antibody development abilities. In 2014, we added antibody phage display technology to help us develop the diverse and specific antibody repertoire to certain difficult targets that might be difficult to achieve with hybridoma technology alone. We have developed camelid (VHH) antibody capabilities so we can service the rapidly growing therapeutics market. We have been offering this service since 2015.
Who are we?
NeoClone is the Midwest's premier custom antibody development company. We are committed to providing the highest quality antibodies for the global research and diagnostic markets while adding sophisticated new capabilities to bolster our entry into the therapeutic antibody market.
What do we do?
We make custom antibodies! Really good ones. Because no one method will work for every project, NeoClone will work with your team to develop the best antibody strategy, from initial project design through assay development, bringing a full set of tools to bear to antibody discovery, characterization, production, purification and screening. NeoClone offers a range of custom services and solutions to identify novel antibody reagents for you, utilizing multiple technology platforms, such as:
- Hybridoma (mouse monoclonal antibodies)
- Antibody phage display (scFv)
- Camelid antibodies (VHH)
- Antigen-specific B-Cell Enrichment (Reactivation)
Few companies have experience in both hybridoma and antibody phage display, much less single domain camelid antibody technologies. Add to that NeoClone's patented antigen-specific B-cell enrichment process (Reactivation) for particularly rare targets and transgenic systems, and you can see why NeoClone is the best choice for maximum antibody diversity and affinity.
We view every project as a partnership, where the goals and results are dependent on the needs of our client.
You tell us what you need. We'll make sure you get it.
Features and Benefits:
NeoClone's wide array of custom antibody services are tailored to your specific requirements.
Samples of antibodies are available to you throughout the process for evaluation in your laboratory.
You receive regular progress reports as the project proceeds.